Share Twitter LinkedIn Facebook Email Jame Abraham, MD @jamecancerdoc of Cleveland Clinic @ClevelandClinic discusses at this year’s virtual ASCO the phase I open label dose escalation and expansion of SGN-LIV1A administered weekly in breast cancer.
Strategizing Personalized Breast Cancer Treatment: A Promising Overview of Advances and Clinical Applications [39 SLIDES] Breast 4 Mins Read
Fertility Preservation: Interrupting endocrine therapy to attempt pregnancy in Breast Cancer Breast 2 Mins Read